Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2
CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of […]